Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

Copyright © 2019. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 203(2019) vom: 15. Juni, Seite 154-161
1. Verfasser: Sciullo, Paula Di (VerfasserIn)
Weitere Verfasser: Menay, Florencia, Cocozza, Federico, Gravisaco, María José, Waldner, Claudia I, Mongini, Claudia
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't CD40 Imiquimod T-cell lymphoma-vaccine TLR Adjuvants, Immunologic Antigens, Neoplasm Cancer Vaccines Cell Extracts mehr... Toll-Like Receptor 7 P1QW714R7M
Online verfügbar Volltext